Shervin J. Korangy

Personal data:

Born: 1974

Gender: Male

Nationality: U.S.-American

Member since: -

Education:

• Bachelor of Science (B.S.) in Economics (The Wharton School, University of Pennsylvania, Philadelphia, Pennsylvania, U.S.)

Professional experience:

2017 - present BVI Medical, Inc., Waltham, Massachusetts, U.S.

- 2019 present: President and Chief Executive Officer (CEO)
- 2017 2019: Chief Financial Officer (CFO) and Chief Strategy Officer (CSO)

2011 Co-founder of Sight Sciences, Inc., Menlo Park, California, U.S.

2010 – 2017 Various positions (including Country/Region Head and Global Head of Corporate Finance) at Novartis AG, Basel, Switzerland

1996 – 2010 Various positions (most recently Managing Director) at The Blackstone Group Inc., New York City, New York, U.S.

Information on memberships of other statutory supervisory boards:

None

Information on memberships in comparable domestic and foreign supervisory bodies of business enterprises:

- BVI Group Ltd., Warwickshire, United Kingdom (non-listed company), member of the Board of Directors (group mandate)
- The Hain Celestial Group, Inc., Lake Success, New York, U.S. (listed company), member of the Board of Directors
- Motus GI Holdings, Inc., Fort Lauderdale, Florida, U.S. (listed company), member of the Board of Directors

Other major activities:

None

Disclosures in accordance with the recommendations of the German Corporate Governance Code (DCGK):

According to the assessment of the supervisory board, there are no personal or business relationships of Mr. Shervin J. Korangy with the Company, its group companies, the governing bodies of the Company or a shareholder with a material interest in the Company that would require disclosure within the meaning of recommendation C.13 DCGK. According to the assessment of the supervisory board, Mr. Shervin J. Korangy is independent within the meaning of recommendation C.7 DCGK.

Dr. Marcus Kuhnert

Personal data:

Born: 1968

Gender: Male

Nationality: German/U.S.-American

Member since: -

Education:

- Degree in Industrial Engineering (*Diplom-Wirtschaftsingenieur*) (Technische Universität Darmstadt, Darmstadt, Germany)
- Dr. rer. pol. (Technische Universität Darmstadt, Darmstadt, Germany)

Professional experience:

2014 - present Member of the Executive Board (general partner) and Chief Finan-

cial Officer (CFO) of MERCK Kommanditgesellschaft auf Aktien, Darmstadt, Germany (until 30 June 2023), and member of the Executive Board (general partner) of E. Merck KG, Darmstadt, Germany

(until 31 July 2024)

1999 – 2014 Various positions (lastly Chief Financial Officer (CFO) of the Laundry

& Home Care business unit) at Henkel AG & Co. KGaA, Dusseldorf,

Germany

Information on memberships of other statutory supervisory boards:

None

Information on memberships in comparable domestic and foreign supervisory bodies of business enterprises:

Döhler Group SE, Darmstadt, Germany (non-listed company), member of the Board of Directors

Other major activities:

None

Disclosures in accordance with the recommendations of the German Corporate Governance Code (DCGK):

According to the assessment of the supervisory board, there are no personal or business relationships of Dr. Marcus Kuhnert with the Company, its group companies, the governing bodies of the Company or a shareholder with a material interest in the Company that would require disclosure within the meaning of recommendation C.13 DCGK. According

to the assessment of the supervisory board, Dr. Marcus Kuhnert is independent within the meaning of recommendation C.7 DCGK.

Gregory Sorensen, M.D.

Personal data:

Born: 1962

Gender: Male

Nationality: U.S.-American

Member since: 2021

Education:

• Doctor of Medicine (M.D.) (Harvard Medical School, Boston, Massachusetts, U.S., and Massachusetts Institute of Technology, Cambridge, Massachusetts, U.S.)

- Master of Science (M.S.) in Computer Science (Brigham Young University, Provo, Utah, U.S.)
- Bachelor of Science (B.S.) in Biology (California Institute of Technology, Pasadena, California, U.S.)

2015 - present Chief Executive Officer (CEO) of DeepHealth Inc., Cambridge, Mas-

Professional experience:

	sachusetts, U.S.
	Executive Chairman of the Board of Directors of IMRIS (Deerfield Imaging, Inc.), Minnetonka, Minnesota, U.S.
2011 – 2015	President and Chief Executive Officer (CEO) of Siemens Medical Solutions USA, Inc., Malvern, Pennsylvania, U.S.
1995 – 2011	Lecturer and Professor at Harvard Medical School, Boston, Massachusetts, U.S.

Neuroradiologist at Massachusetts General Hospital, Boston, Massachusetts, U.S.

Information on memberships of other statutory supervisory boards:

Fresenius Medical Care Management AG, Hof (Saale), Germany (non-listed company), member of the supervisory board (group mandate)

Information on memberships in comparable domestic and foreign supervisory bodies of business enterprises:

REALM IDx, Inc., Aliso Viejo, California, U.S. (non-listed company), Non-Executive Director

Other major activities:

None

Disclosures in accordance with the recommendations of the German Corporate Governance Code (DCGK):

Mr. Gregory Sorensen, M.D., is currently a member of the supervisory board of Fresenius Medical Care Management AG, the general partner of the Company, from which he will resign upon effectiveness of the conversion. In addition, Fresenius Medical Care Management AG will cease to be the Company's general partner upon effectiveness of the conversion. According to the assessment of the supervisory board, upon effectiveness of the conversion, there are no personal or business relations of Mr. Gregory Sorensen, M.D., with the Company, its group companies, the governing bodies of the Company or a shareholder with a material interest in the Company that would require disclosure within the meaning of recommendation C.13 DCGK. According to the assessment of the supervisory board, Mr. Gregory Sorensen, M.D., is independent within the meaning of recommendation C.7 DCGK.

Pascale Witz

Personal data:

Born: 1967

Gender: Female

Nationality: French

Member since: 2016

Education:

 Diplome d'Ingenieur in Biochemistry (Institut National des Sciences Appliquées (INSA), France)

• M.B.A. in Business Administration (INSEAD, France)

Professional experience:

2016 – present	President of PWH Advisors LLC, New York City, New York, U.S.
2013 – 2016	Executive Vice President of Sanofi S.A., Paris, France
2009 – 2013	President and Chief Executive Officer (CEO) of GE Healthcare, Medical Diagnostics Division, London, United Kingdom
2008 – 2009	President and General Manager, Interventional Radiology & Cardiology of GE Healthcare Corporation, Milwaukee, Wisconsin, U.S.
1996 – 2007	Various positions in France and the U.S. at GE Healthcare Corporation, Milwaukee, Wisconsin, U.S.
1991 – 1996	Marketing Manager, Pharmaceuticals Systems Europa, at Becton Dickinson Corporation, Franklin Lakes, New Jersey, U.S.

Information on memberships of other statutory supervisory boards:

Fresenius Medical Care Management AG, Hof (Saale), Germany, (non-listed company), member of the supervisory board (group mandate)

Information on memberships in comparable domestic and foreign supervisory bodies of business enterprises:

- Horizon Therapeutics plc, Dublin, Ireland (publicly-listed company), Non-Executive Director
- Revvity, Inc., Waltham, Massachusetts, U.S. (publicly-listed company), Non-Executive Director

 Regulus Therapeutics Inc., San Diego, California, U.S. (publicly-listed company), Non-Executive Director

Other major activities:

Advisor to healthcare and life sciences companies and investment firms

Disclosures in accordance with the recommendations of the German Corporate Governance Code (DCGK):

Ms. Pascale Witz is currently a member of the supervisory board of Fresenius Medical Care Management AG, the general partner of the Company, from which she will resign upon effectiveness of the conversion. In addition, Fresenius Medical Care Management AG will cease to be the Company's general partner upon effectiveness of the conversion. According to the assessment of the supervisory board, upon effectiveness of the conversion, there are no personal or business relations of Ms. Pascale Witz with the Company, its group companies, the governing bodies of the Company or a shareholder with a material interest in the Company that would require disclosure within the meaning of recommendation C.13 DCGK. According to the assessment of the supervisory board, Ms. Pascale Witz is independent within the meaning of recommendation C.7 DCGK.

Michael Sen

Personal data:

Born: 1968

Gender: Male

Nationality: German

Member since: -

Education:

- Commercial Assistant (*Industriekaufmann*) (Siemens Aktiengesellschaft, Berlin/Munich, Germany (Siemens apprenticeship))
- Degree in Business Administration (*Diplom-Kaufmann*) (Technische Universität Berlin (TUB), Berlin, Germany)

Professional experience:

April 2021 – present Fresenius Group, Bad Homburg v. d. Höhe, Germany

- 10/2022 present: Chairman of the management board of Fresenius Management SE
- 04/2021 02/2023: Chairman of the management board of Fresenius Kabi Aktiengesellschaft and member of the management board of Fresenius Management SE (responsible for the business segment Fresenius Kabi)

2017 – 2021 Siemens Aktiengesellschaft, Berlin/Munich, Germany

- 04/2020 03/2021: Executive Advisor of the Chief Executive Officer and of the Chairman of the supervisory board
- 10/2019 03/2020: Member of the management board (responsible for Energy, among other responsibilities)
- 04/2017 09/2019: Member of the management board ((Executive) Chairman Siemens Healthineers, among other responsibilities)

2015 – 2017 Member of the management board (Chief Financial Officer (CFO)) at E.ON SE, Essen, Germany

Various positions (lastly member of the management board Healthcare Sector and Chief Financial Officer (CFO)) at Siemens Aktiengesellschaft, Munich, Germany

Information on memberships of other statutory supervisory boards:

- Fresenius Kabi Aktiengesellschaft, Bad Homburg v. d. Höhe, Germany (non-listed company), chairman of the supervisory board (group mandate)
- Fresenius Medical Care Management AG, Hof (Saale), Germany (non-listed company), chairman of the supervisory board (group mandate)

Information on memberships in comparable domestic and foreign supervisory bodies of business enterprises:

None

Other major activities:

None

Disclosures in accordance with the recommendations of the German Corporate Governance Code (DCGK):

Mr. Michael Sen is a member and chairman of the supervisory board of Fresenius Medical Care Management AG, the general partner of the Company, which will cease to be a general partner of the Company upon effectiveness of the conversion. He is also a member and chairman of the management board of Fresenius Management SE, the general partner of Fresenius SE & Co. KGaA. Fresenius SE & Co. KGaA holds approximately 32.2% of the share capital and the voting rights of the Company. Even after the effectiveness of the conversion, the Company will continue to have a material business relationship with Fresenius SE & Co. KGaA or its affiliated companies. Mr. Michael Sen is therefore, as a matter of precaution, not considered independent within the meaning of recommendation C.7 DCGK. According to the assessment of the supervisory board, there are no further personal or business relationships of Mr. Michael Sen with the Company, its group companies, the governing bodies of the Company or a shareholder with a material interest in the Company that would require disclosure pursuant to recommendation C.13 DCGK.

Sara Lisa Hennicken

Personal data:

Born: 1980

Gender: Female

Nationality: Germany

Member since: -

Education:

Diplom-Ökonom (Justus-Liebig-Universität, Gießen, Germany)

Master of Arts in Economics (University of Wisconsin-Milwaukee (UVM), Milwaukee, Wisconsin, U.S.)

Professional experience:

2019 – present Fresenius Group, Bad Homburg v. d. Höhe, Germany

- 09/2022 present: Member of the management board (Chief Financial Officer)
- 08/2019 2022: Senior Vice President Global Treasury and Corporate Finance
- 2010 2019 Various positions (lastly Managing Director and Senior Client Executive in Corporate Finance Coverage) at Deutsche Bank AG, Frankfurt am Main, Germany, and London, United Kingdom
- 2005 2010 Various positions (lastly Associate, Investment Banking, Corporate Finance) at Citigroup, Frankfurt am Main, Germany, and London, United Kingdom

Information on memberships of other statutory supervisory boards:

- Fresenius Kabi Aktiengesellschaft, Bad Homburg v. d. Höhe, Germany, (non-listed company), Deputy chair of the supervisory board (group mandate)
- Fresenius Medical Care Management AG, Hof (Saale), Germany, (non-listed company), member of the supervisory board (group mandate)

Information on memberships in comparable domestic and foreign supervisory bodies of business enterprises:

VAMED AG, Vienna, Austria, (non-listed company), Deputy Chair of the supervisory board (group mandate)

Other major activities:

None

Disclosures in accordance with the recommendations of the German Corporate Governance Code (DCGK):

Ms. Sara Lisa Hennicken is a member of the supervisory board of Fresenius Medical Care Management AG, the general partner of the Company, which will cease to be a general partner of the Company upon effectiveness of the conversion. She is also a member of the management board of Fresenius Management SE, the general partner of Fresenius SE & Co. KGaA. Fresenius SE & Co. KGaA holds approximately 32.2% of the share capital and the voting rights of the Company. Even after the effectiveness of the conversion, the Company will continue to have a material business relationship with Fresenius SE & Co. KGaA or its affiliated companies. Ms. Sara Lisa Hennicken is therefore, as a matter of precaution, not considered independent within the meaning of recommendation C.7 DCGK. According to the assessment of the supervisory board, there are no further personal or business relationships of Ms. Sara Lisa Hennicken with the Company, its group companies, the governing bodies of the Company or a shareholder with a material interest in the Company that would require disclosure pursuant to recommendation C.13 DCGK.